NBI-1065845

· Neurocrine Biosciences

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for NBI-1065845, covering 2025-01-15 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) [Phase 3]

See pricing